Spinal muscular atrophy is a genetic disease that weakens muscles throughout the body. It's caused by low levels of the SMN protein, which motor neurons need to survive. Three approved therapies — nusinersen, onasemnogene abeparvovec, and risdiplam — now change the course of SMA, especially when started early. Most trials today focus on improving what these drugs can do.
What's actually going on in research
Trials are testing combination approaches that pair existing SMN-restoring drugs with muscle-building treatments, neuroprotective agents, or gene therapy refinements. Researchers are also studying physical therapy protocols tailored to SMA, assistive technology for daily function, and biomarkers that predict how well someone will respond to treatment. Some work explores late-onset SMA, where treatment patterns are less clear.
Combination therapies
Several trials combine SMN-restoring drugs with myostatin inhibitors or other muscle-building agents. The goal is to strengthen muscle tissue after motor neurons are protected.
Gene therapy improvements
Researchers are testing next-generation gene therapies with different viral vectors or dosing strategies. Some aim to reach older children and adults who weren't eligible for the first-generation therapy.
Rehabilitation science
Studies are defining the right physical therapy intensity and type for people on SMN drugs. Early findings suggest structured exercise may safely build function beyond what medication alone achieves.
What to know before you search
Eligibility typically depends on SMA type, age at symptom onset, current motor function, whether you've received prior SMN-restoring therapy, and genetic confirmation of SMN1 deletion or mutation.
What types of trials are currently open
- Drug combination trials — Testing whether adding a muscle-building drug to nusinersen, risdiplam, or gene therapy produces better strength gains than SMN therapy alone.
- Gene therapy trials — Studying refined or second-generation gene therapies, sometimes for people who didn't receive the first-approved version or who have later-onset SMA.
- Rehabilitation trials — Testing specific physical therapy programs or assistive devices to see what safely improves mobility and daily function in people on SMN-restoring treatment.
- Natural history studies — Following people with SMA over time to understand how the disease progresses with and without treatment, and what factors predict outcomes.
- Biomarker studies — Measuring proteins or other markers in blood or spinal fluid to predict treatment response and track disease activity.
Recently added Spinal Muscular Atrophy trials
Join a registry tracking prenatal spinal muscular atrophy care and baby outcomes
Because no long-term record of prenatal Spinal Muscular Atrophy (SMA) treatment exists, this study will address an important gap in the understanding of the safety and benefit of treatment while in the womb. The registry will help guide best practices for monitoring pregnant women and their fetus with SMA, if treated with a medication while in the womb, and to follow the baby after birth for signs of safety and added benefit birth and support future research and study development.
Donate blood samples to advance brain disease research
The aim of this study is to contribute to and continue to sustain a repository of blood samples, nucleic acid (DNA and/or RNA) samples, family history information, and other demographic information from individuals with age-related neurodegenerative conditions, or their family members who may or may not be at risk for similar conditions. This study will continue to further expand research into the molecular and genetic basis of these diseases and their risk factors.
Find Spinal Muscular Atrophy trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.